The FDA issued a warning letter to Novo Nordisk for misreporting and failing to investigate potentially serious side effects of its popular GLP-1 drugs.[5] The letter was dated March 5 and published on Tuesday. The FDA reported three deaths in patients taking these drugs, including one suicide, that the company did not report in time.[5] These cases also included strokes. Novo Nordisk failed to report and investigate these incidents as required by law.[5] The warning comes amid high demand for GLP-1 drugs for obesity and diabetes.[1]